Key clinical point: Treatment with once-daily oral abrocitinib led to significantly greater improvements in patient-reported outcomes than placebo in patients with moderate-to-severe atopic dermatitis (AD).
Major finding: At week 16, the patient-oriented eczema measure score improved significantly for 100 mg abrocitinib (least square mean change from baseline [LSM] −9.2) and 200 mg abrocitinib (LSM −12.5) vs. placebo ( −5.0; P for both < .0001 ). A significantly higher proportion of patients receiving abrocitinib, both 200 mg and 100 mg, than placebo reported clinically meaningful improvement in pruritus and symptoms assessment for AD and patient global assessment response (all P < .05 ).
Study details: Findings are from a phase 3 JADE COMPARE study including 837 patients with moderate-to-severe AD who were randomly assigned to receive 200 mg abrocitinib, 100 mg abrocitinib, dupilumab, or placebo, with background topical therapy.
Disclosures: This study was funded by Pfizer. The authors declared serving as a consultants, speakers, advisors, and investigators or receiving grants from Pfizer and other sources. Six authors declared being employees and shareholders of Pfizer.
Source: Thyssen JP et al. J Eur Acad Dermatol Venereol. 2021 (Nov 15). Doi: 10.1111/jdv.17813.